Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT06912087 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT06912087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06912087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Recruiting
Start date
September 29, 2025
Completion date
June 5, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, head and neck neoplasms, metastatic squamous cell carcinoma, neoplasm metastasis, neoplasm recurrence, local, recurrent squamous cell carcinoma